key: cord-0819321-oul5bnhy authors: Sun, Yaping; Ho, Mitchell title: Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic date: 2020-11-24 journal: Antib Ther DOI: 10.1093/abt/tbaa025 sha: 379362a055956f7da172f88e2d4c5255e89e9f94 doc_id: 819321 cord_uid: oul5bnhy SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As of October 11, 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike protein have entered clinical trials with three (REGN-COV2, LY3819253/LY-CoV555, and VIR-7831/VIR-7832) in phase 3. On November 9, 2020, the US FDA issued an emergency use authorization for bamlanivimab (LY3819253/LY-CoV555) for the treatment of mild-to-moderate COVID-19. This review outlines the development of neutralizing antibodies against SARS-CoV-2, with a focus on discussing various antibody discovery strategies (animal immunization, phage display and B cell cloning), describing binding epitopes and comparing neutralizing activities. Broad-neutralizing antibodies targeting the spike proteins of SARS-CoV-2 and SARS-CoV might be helpful for treating COVID-19 and future infections. VIR-7831/7832 based on S309 is the only antibody in late clinical development, which can neutralize both SARS-CoV-2 and SARS-CoV although it does not directly block virus receptor binding. Thus far, the only cross-neutralizing antibody that is also a receptor binding blocker is nanobody VHH-72. The feasibility of developing nanobodies as inhaled drugs for treating COVID-19 and other respiratory diseases is an attractive idea that is worth exploring and testing. A cocktail strategy such as REGN-COV2, or engineered multivalent and multispecific molecules, combining two or more antibodies might improve the efficacy and protect against resistance due to virus escape mutants. Besides the receptor-binding domain, other viral antigens such as the S2 subunit of the spike protein and the viral attachment sites such as heparan sulfate proteoglycans are on the host cells are worth investigating. U N C O R R E C T E D M A N U S C R I P T This review summarizes ongoing efforts to develop neutralizing antibodies against SARS-CoV-2 with a focus on targets, neutralizing activities and screening strategies, including phage display, animal immunization and B cell cloning. A cocktail strategy combining two or more antibodies, including nanobodies, targeting different epitopes might protect against mutant resistance. Coronaviruses (CoVs) are potentially lethal pathogens, with 7 strains having emerged to infect humans in recent years. Human coronavirus-229E (HCoV-229E) and HCoV-OC43 were identified in the 1960s and reported to cause symptoms similar to that of a mild common cold, except in infants, the elderly, and the immunocompromised (7) (8) (9) . Decades later, in 2002-2003, outbreak of SARS-CoV infection became a global pandemic (10, 11) . SARS-CoV is thought to be an animal virus from its natural reservoir, perhaps bats, that spread to other animals (civet cats) as an intermediate host in animal-to-human transmission (12, 13) . Patients infected with SARS-CoV exhibited atypical pneumonia that had the potential to progress to acute respiratory distress syndrome (14) . S C R I P T fatality rate: 9.56%) (15) . Two more coronaviruses, HCoV-NL63 and HCoV-HKU1, were found in 2004-2005 from archived nasopharyngeal aspirates and caused mild to serious lower respiratory tract infections (16) (17) (18) . In 2012, almost a decade after the first SARS-CoV outbreak, the Middle East respiratory syndrome coronavirus (MERS-CoV) caused a total of 2494 laboratory-confirmed cases, including 858 associated deaths (case-fatality rate: 34.4%) globally (19) . It was reported that MERS-CoV has the same receptor usage and cell entry as bat coronavirus HKU4 which provides an insight into bat-to-human transmission of MERS-CoV (20, 21) . In December 2019, cases of mysterious pneumonia were reported in Wuhan, Hubei Province, China which were later confirmed to be caused by a new coronavirus named SARS-CoV-2. Although bats are probable reservoir hosts for the new coronavirus (22) , any intermediate host that may facilitate transfer to humans has not been identified. While the researchers have isolated a coronavirus from a Malayan pangolin, the S protein receptor-binding domain (RBD) of pangolin-CoV is similar to that of SARS-CoV-2 (23, 24) , indicating pangolin could be a potential intermediate host. It has been speculated that SARS-CoV-2 might be the result of a recombination between bat (RaTG13) and pangolin coronaviruses based on the analysis of the S protein sequences (25) . The SARS-CoV-2 S protein contains a few residues (e.g., F486 and N501) for stronger contacts with human angiotensin converting enzyme 2 (ACE2) (26) . These residues are also found in the sequence of pangolin coronavirus (27) . CoVs are enveloped viruses containing single-stranded positive-sense RNA that belongs to the Coronaviridae family of the Orthocoronavirinae subfamily which can cause illness in animals and humans. CoVs are a large family that is genotypically and phenotypically diverse. CoVs can be divided into four distinct groups based on the genomic sequence alignment phylogenetically, defined as α, β, γ and δ. β-coronaviruses may further be subgrouped as lineage a, b, c, d in classical taxonomy. Both SARS-CoV and SARS-CoV-2 belong to β-genus lineage b, while MERS-CoV belongs to β-genus lineage c. HCoV-OC43 and HCoV-HKU1 are βgenus lineage a, HCoV-229E and HCoV-NL63 are α-genus (28, 29) . The SARS-CoV-2 viral genome of about 27-32 kb encodes for structural and non-structural proteins. The structural proteins include membrane (M) protein, envelope (E) protein, nucleocapsid (N) protein, and spike (S) protein. The S protein plays a role in viral entry and is crucial for determining host tropism and transmission capacity (30) (31) (32) . The S protein mainly consists of two functional subunits, S1 and S2. S1 is responsible for host cell receptor binding, while S2 is responsible for viral and cellular membrane fusion (33) . For many CoVs, the S protein is cleaved between the S1 and S2 subunits, which can activate the protein for membrane fusion (34) (35) (36) (37) (38) . CoVs entry into susceptible cells is a complex process that requires the process of receptor-binding and proteolytic processing of the S protein to cause the virus-cell fusion. A recent report about the molecular assembly of the authentic SARS-CoV-2 virus at average resolutions of 8.7-11 Å largely confirms previous observations using recombinant S proteins (42). The biological explanation for the tilted S trimer on the virion is unclear. It might be possible that they represent different prefusion stages of the S protein. Based on the S protein sequence alignment, the overall similarities between SARS-CoV-2 S and SARS-CoV S (isolated from human, civet, or bat) are approximately 76% to 78% for the whole protein, and 73% to 76% for the receptor binding domain (RBD) (22, 39, 43 ). The sequence similarity may partly explain why SARS-CoV-2 and SARS-CoV share the receptor ACE2 on host cells. Additionally, this shared characteristic may provide the rationale or possibility to develop cross-neutralizing antibodies to both of CoVs (27, 39, 44, 45) . The U.S. Food and Drug Administration (FDA) has approved the repurposing of some drugs as emergency treatment for severe COVID-19 patients (46). However, major ongoing preclinical and clinical studies have focused on identifying anti-SARS-CoV-2 antibodies targeting its spike protein, thereby blocking virus entry effectively (27, 47) . Three antibody drugs specific for the S protein targeting other antigens are also under investigation and will be discussed later in this review. Neutralizing monoclonal antibodies against the S protein may block virus entry. The RBD located in the S protein is responsible for host cell receptor binding, making it a primary target of neutralizing antibody development (27) . There are two conformations, prefusion and postfusion, for the S trimer structure (40 Animal immunization has also been used to isolate antibodies targeting SARS-CoV-2 S protein. Wang cloning of the human variable regions into a human IgG1 framework (58) . Taken together, animal immunization with S protein from multiple CoVs is an efficient way to identify cross-neutralizing antibodies. As the most popular strategy so far, single B-cell cloning allows for the rapid generation of antigen-specific monoclonal antibodies in a matter of several weeks, which is highly-efficient for antibody development against emerging infectious virus (59). Pinto et al. In order to overcome virus escape mutation, Regeneron has described parallel efforts utilizing both animal immunization (geneticallyhumanized mice) and B cell cloning from convalescent humans to generate a large collection of highly-potent human neutralizing animal studies before they can be used in humans. Some studies have investigated the changes of several cytokines in serum of the COVID-19 patients that generates a series of immune responses, and the cytokine storm syndrome was proportional to the severity of disease (3, 4, 77) . The pro-inflammatory cytokine IL-6 may have a prominent role, leading to the inflammatory cascade, which may result in increased alveolar-capillary blood-gas exchange dysfunction (78, 79) . Antibodies targeting IL-6 such as Olokizumab, Siltuximab are in phase 3 trial at present. Clinically, Stoclin et al. reported the case of a patient with a respiratory failure linked to COVID-19 who had a rapid favorable outcome after two infusions of Tocilizumab, an anti-IL-6 receptor antibody (80 (83)) for SARS-CoV-2 attachment would be useful for designing specific anti-viral inhibitors. There are 13 clinical trials ongoing related to human monoclonal antibodies targeting SARS-CoV-2 spike protein described in Table 2 . According to the COVID-19 Antibody Therapeutics JS016, which is discussed above as antibody CB6, is the first SARS-CoV-2 neutralizing antibody to enter clinical trials in China. antibodies (92, 93) . Naturally occurring nanobodies derived from camels (61, (94) (95) (96) and sharks (92, (97) (98) (99) are stable and relatively easy to express and fold in various conditions; therefore, they can be effective building blocks for the construction of multivalent and multispecific molecules to effectively neutralize virus. When revising this review article, another paper reported nanobodies (e.g., Nab20, Nab21) isolated from a RBD-immunized llama with picomolar to femtomolar affinities that inhibit SARS-CoV-2 viral infection at sub-ng/ml concentration (100) . Furthermore, multivalent nanobody constructs can achieve high neutralization potency (IC 50 s as low as 0.058 ng/ml). For respiratory infection such as COVID-19, nanobodies are particularly attractive because they might be administered as an inhaler directly to the site of infection (101) . Further studies are necessary to evaluate the feasibility of developing nanobody-based therapeutics as inhaled drugs for treating COVID-19 and other respiratory infections. Around 85% of antibodies are developed targeting the S protein, primarily focused on targeting RBD in an effort to block the viral entry at the initial step of binding to the host cell receptor. In the perspective of cross-neutralizing antibody development for SARS related CoVs, it seems antibody derived from SARS-CoV patient or SARS-CoV immunization animals could have the crossneutralizing activities on SARS-CoV-2. However, antibodies derived from SARS-CoV-2 patients usually do not show crossneutralizing ability on SARS-CoV. Although both S proteins from SARS-CoV-2 and SARS-CoV bind human ACE2 on the cells for viral entry and both S proteins have highly similar structures, hypothetically an ACE2 blocker that can neutralize both viruses is feasible. However, it seems rare to identify such a shared epitope using existing SARS-CoV-2 antibodies. This apparent discrepancy will require further investigation on the structure and function of the S protein of these two viruses. Cross-neutralizing antibodies are being explored by using various strategies, including single domain antibodies. Next generation sequencing of neutralizing antibodies against SARS-CoV-2 has been conducted in several studies. In Regeneron's study, over 200 antibodies isolated from humanized mice show predominant lineage of antibodies utilizes VH3-53 paired with VK1-9, I P T VK1-33, or VK1-39, while antibodies isolated from infected humans utilize VH3-66 paired with VK1-33 or VH2-70 paired with VK1-39. Interestingly, VH3-53 usage (e.g., VH3-53/VK1-9 pair (102)) has been found in other human-derived neutralizing antibody against SARS-CoV-2 spike protein (72, 102) . In a recent study conducted by Eli Lilly, sequencing of about 400 antibodies shows that the VH3 germline gene family (e.g., VH3-53, VH3-66) representing 57% of total diversity. Among them, VH3-30 usage is the most common (38%). However, the selected Ab169 (LY-CoV555) has VH1-69 and VK1-39 germline framework sequences. Further sequence analysis of neutralizing antibodies against SARS-CoV-2 RBD might provide valuable insights of the usage of germline sequences for potent anti-viral neutralizing activities. Such information could be useful for not only therapeutic antibody development or optimization but also vaccine or adjuvant design. Antibody targeting S2 subunit may also worth studying since it shows more overall sequence similarity not only between SARS-CoV and SARS-CoV-2, also among other human coronaviruses. Up to date, antibodies targeting S2 with potent neutralization activities against SARS-CoV-2 have not been reported. It appears challenging to isolate antibodies to S2 probably due to the dynamic structure of the S2 subunit as part of the virus spike trimer and elusive conformational change at the fusion stage. Further biochemical studies of the S2 subunit and establishment of a suitable screening assay might be crucial for generating neutralizing antibodies targeting S2. Antibodies specific for host targets including the viral attachment sites on human cells such as heparan sulfate should be explored as well. A cocktail combination therapy targeting target two or more distinct sites or pathways on the viral surface or host attachment The review is focused on discussing screening strategies for isolating neutralizing antibodies against SARS-CoV-2 and their functional properties. We are also aware such antibodies with high affinity and specificity, including nanobodies, can also be utilized as detectors for diagnostics (107) . A microfluidic device or magnetic beads using antibodies highly specific for viral proteins can be developed to capture virus for detection (108) . When preparing this review, U.S. President Trump and the First Lady were diagnosed with COVID-19 on October 1, 2020 MH is the Editor-in-Chief of the journal and is blinded from reviewing or making decisions on the manuscript. A Novel Coronavirus from Patients with Pneumonia in China A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical features of patients infected with 2019 novel coronavirus in Wuhan Emerging understandings of 2019-nCoV The first 2019 novel coronavirus case in Nepal Cultivation of a Novel Type of Common-Cold Virus in Organ Cultures A new virus isolated from the human respiratory tract Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease A novel coronavirus associated with severe acute respiratory syndrome Severe acute respiratory syndrome Bats are natural reservoirs of SARS-like coronaviruses Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human Coronavirus as a possible cause of severe acute respiratory syndrome The chronology of the 2002-2003 SARS mini pandemic A previously undescribed coronavirus associated with respiratory disease in humans Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26 A pneumonia outbreak associated with a new coronavirus of probable bat origin Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins The proximal origin of SARS-CoV-2 Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Perspectives on the development of neutralizing antibodies against SARS-CoV-2 Coronaviruses post-SARS: update on replication and pathogenesis A decade after SARS: strategies for controlling emerging coronaviruses The molecular biology of coronaviruses Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond Structure, Function, and Evolution of Coronavirus Spike Proteins Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein Identification of Human Single-Domain Antibodies against SARS-CoV-2 In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin Directed evolution of antibody fragments with monovalent femtomolar antigenbinding affinity Yeast surface display for screening combinatorial polypeptide libraries Isolation of anti-CD22 Fv with high affinity by Fv display on human cells 2020) A human monoclonal antibody blocking SARS-CoV-2 infection An Efficient Method to Generate Monoclonal Antibodies from Human B Cells Crossneutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics Structural and molecular basis for Ebola virus neutralization by protective human antibodies Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies Genomic evidence for reinfection with SARS-CoV-2: a case study Potently neutralizing and protective human antibodies against SARS-CoV-2 Human neutralizing antibodies elicited by SARS-CoV-2 infection A human neutralizing antibody targets the receptor binding site of SARS-CoV-2 Convergent antibody responses to SARS-CoV-2 in convalescent individuals Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies Pathological findings of COVID-19 associated with acute respiratory distress syndrome Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 Infectious Entry and Neutralization of Pathogenic JC Polyomaviruses Human papillomavirus capsids preferentially bind and infect tumor cells Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7 Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy Isolation of Antibodies to Heparan Sulfate on Glypicans by Phage Display Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. 2020 Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura Crystal structure of a shark single-domain antibody V region in complex with lysozyme Inaugural Editorial: Searching for Magic Bullets Naturally occurring antibodies devoid of light chains Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naive nurse sharks Ancient species offers contemporary therapeutics: an update on shark VNAR single domain antibody sequences, phage libraries and potential clinical applications A cold-blooded view of adaptive immunity Versatile and multivalent nanobodies efficiently neutralize SARS-CoV Nanobodies® as inhaled biotherapeutics for lung diseases Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells Dissecting antibody-mediated protection against SARS-CoV-2 Structural and functional analysis of a potent sarbecovirus neutralizing antibody Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail Antibody responses to SARS-CoV-2 in patients with COVID-19 Microfluidic devices for the detection of viruses: aspects of emergency fabrication during the COVID-19 pandemic and other outbreaks Simultaneous and automated detection of influenza A virus hemagglutinin H7 and H9 based on magnetism and size mediated microfluidic chip. Sensors and actuators. B, Chemical, 308, 127675. References VHH-72-Fc Llama VHH, fused to hIgG1 Fc SARS-CoV RBD was used for phage panning by an immunized llama library RBD Pseudovirus SARS-CoV H11-H4-Fc Llama VHH, fused to hIgG1 Fc SARS-CoV-2 RBD was used for phage panning by a naïve llama library RBD Live SARS-CoV-2 IC50 4-6 nM Jiangdong Huo, et.al Ty1 Alpaca VHH Immunized one alpaca with SARS-CoV-2 S1-Fc and RBD on a 60-day immunization schedule RBD Pseudoviruse SARS-CoV-2 IC50 of 0.77 µg/mL Human VH SARS-CoV-2 S1 was used for phage panning by an engineered human VH library cryptic epitope located in the spike trimeric interface Live SARS-CoV-2 IC50 ~2 Live SARS-CoV IC50 0.19 μg/mL (1.2 nM) Live SARS-CoV-2 P2C-1A3 Human IgG1 Single B cell antibody isolation of 8 SARS-CoV-2 infected individuals RBD live SARS-CoV-2 2020 (69) CB6 Human IgG1 Utilized SARS-CoV-2 RBD as the bait to sort specific memory B cells PBMCs of a convalescent COVID-19 patient Overlapping with ACE2-binding sites in SARS-CoV-2 RBD Live virus IC50 36 ng/mL (0.24 nM) CB6 (50 mg/kg) inhibited SARS-CoV-2 infection in rhesus monkeys at both prophylactic and treatment settings Live SARS-CoV-2 IC100 22 ng/mL (0.14 nM) CC12.1 (4 mg/kg) inhibited SARS-CoV-2 infection in Syrian hamsters in prophylaxis setting Live SARS-CoV-2 IC50 of 7 and 9 ng/mL 2020 (73) 4A8 Human IgG1 Single B cells antibody isolation of 10 COVID-19 recovered patients with different ages and different infection phase NTD Live SARS-CoV-2 IC50 0.6ug/mL (4 nM)